---
created: '2026-02-08T19:25:12.893727Z'
description: A genetically determined, highly atherogenic lipoprotein consisting of
  an LDL-like particle bound to apolipoprotein(a). Independent risk factor for cardiovascular
  disease.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/Biomarker/lpa/
slug: lpa
tags:
- Biomarker
- biomarker
title: Lp(a)
type: Biomarker
updated: '2026-02-08T19:25:12.893727Z'
---

# Lp A

## Overview

**Lipoprotein(a)**, or **Lp(a)**, is a unique lipoprotein particle. It is essentially an LDL ("bad cholesterol") particle that has a second protein, **apolipoprotein(a)** or apo(a), attached to it via a disulfide bridge.

Unlike LDL cholesterol, Lp(a) levels are determined almost entirely (>90%) by genetics (specifically the *LPA* gene) and are not significantly influenced by diet or lifestyle.

## Pathophysiology

Lp(a) is a "triple threat" for cardiovascular disease:
1.  **Atherogenic:** Like LDL, it can penetrate arterial walls and deposit cholesterol, forming plaque.
2.  **Pro-thrombotic:** The apo(a) protein is structurally similar to plasminogen but lacks enzymatic activity. It competes with plasminogen for binding sites, inhibiting clot breakdown (fibrinolysis) and promoting clot formation.
3.  **Pro-inflammatory:** It carries oxidized phospholipids (OxPL), which trigger inflammation in blood vessel walls.

## Clinical Significance

- **Independent Risk Factor:** Elevated Lp(a) is a causal risk factor for myocardial infarction (heart attack), ischemic stroke, and aortic valve stenosis.
- **Residual Risk:** Explains why some people have heart attacks despite having normal LDL cholesterol.
- **Testing:** Recommendations are shifting towards testing Lp(a) at least once in every adult's lifetime.

## Management

Lp(a) is notoriously difficult to lower.
- **Statins:** Do NOT lower Lp(a) and may slightly increase it.
- **PCSK9 Inhibitors:** Can reduce Lp(a) by 20-30%.
- **Niacin:** Lowers levels but did not show clinical benefit in trials.
- **Emerging Therapies:** Antisense oligonucleotides (e.g., Pelacarsen) and siRNAs (e.g., Olpasiran) in clinical trials show potent reductions >80%.

## Relationships

ASSOCIATED_WITH_GENE::[[LPA Gene]] - Determines >90% of levels
RISK_FACTOR_FOR::[[Cardiovascular Disease]] - Independent causal factor
RISK_FACTOR_FOR::[[Aortic Valve Stenosis]]
RISK_FACTOR_FOR::[[Myocardial Infarction]]
SIMILAR_TO::[[LDL]] - Structural core
INHIBITS::[[Plasminogen]] - Pro-thrombotic mechanism
AFFECTED_BY::[[PCSK9 Inhibitors]] - Modest reduction
UNAFFECTED_BY::[[Diet]] - Generally resistant to lifestyle change
UNAFFECTED_BY::[[Statins]]

## ðŸ’Š Supplements That Affect This Biomarker

No supplement effects documented yet. Add effects in the respective supplement notes.

## ðŸ§ª Lab Tests That Measure This Biomarker

No lab tests linked yet. Add biomarker measurements in the respective lab test notes.

## References

- Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711.
- Nordestgaard BG, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53.


<!-- NEO4J_CONTENT_START -->
## Relationships
### Related
- â†’ [[Lp_A]] (entity)
```yaml
last_modified: '2026-01-26T07:07:14.579785'
source: obsidian
```
- â†’ [[Lp_A]] (biomarker)
```yaml
last_modified: '2026-01-26T07:07:14.579785'
source: obsidian
```
<!-- NEO4J_CONTENT_END -->